KOSDAQ - Delayed Quote KRW
Mezzion Pharma Co.,Ltd. (140410.KQ)
39,150.00
-1,250.00
(-3.09%)
At close: May 2 at 3:30:30 PM GMT+9
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
8,611,620.88
8,611,620.88
31,720,932.23
30,726,176.39
26,653,873.35
Cost of Revenue
6,701,276.83
6,701,276.83
27,836,492.05
31,039,620.91
22,955,589.90
Gross Profit
1,910,344.05
1,910,344.05
3,884,440.18
-313,444.52
3,698,283.45
Operating Expense
16,209,895
16,209,895
18,373,007
23,017,835
20,495,840
Operating Income
-14,299,550.95
-14,299,550.95
-14,488,566.82
-23,331,279.52
-16,797,556.55
Net Non Operating Interest Income Expense
1,130,696.30
1,130,696.30
1,311,830.76
339,904.84
-17,183.34
Pretax Income
-14,533,803.60
-14,533,803.60
-12,480,302.92
-35,909,597.52
-13,025,609.76
Tax Provision
4,942,970.97
4,942,970.97
248,073.46
388,232.61
577,064.64
Net Income Common Stockholders
-19,476,774.57
-19,476,774.57
-12,728,376.38
-36,297,830.14
-13,602,674.40
Basic EPS
-653.00
--
-451.00
-1.36k
-509.67
Diluted EPS
-653.00
--
-451.00
-1.36k
-509.67
Basic Average Shares
29,826.61
--
28,222.56
26,728.89
26,687.42
Diluted Average Shares
29,826.61
--
28,222.56
26,728.89
26,687.42
Total Operating Income as Reported
-14,299,550.64
-14,299,550.64
-14,488,566.14
-23,331,280.10
-16,797,556.31
Rent Expense Supplemental
295,453
295,453
281,641
418,504
254,826
Total Expenses
22,911,171.83
22,911,171.83
46,209,499.05
54,057,455.91
43,451,429.90
Net Income from Continuing & Discontinued Operation
-19,476,774.57
-19,476,774.57
-12,728,376.38
-36,297,830.14
-13,602,674.40
Normalized Income
-19,072,688.65
-19,072,688.65
-12,688,889.82
-25,642,687.84
-13,494,242.40
Interest Income
1,431,485
1,431,485
1,476,640
763,349
306,228
Interest Expense
300,789
300,789
315,460
423,444
323,412
Net Interest Income
1,130,696.30
1,130,696.30
1,311,830.76
339,904.84
-17,183.34
EBIT
-14,233,014.60
-14,233,014.60
-12,164,842.92
-35,486,153.52
-12,702,197.76
EBITDA
-13,275,218.60
-13,275,218.60
-10,618,425.92
-33,827,846.52
-11,116,146.76
Reconciled Cost of Revenue
6,701,276.83
6,701,276.83
27,836,492.05
31,039,620.91
22,955,589.90
Reconciled Depreciation
957,796
957,796
1,546,417
1,658,307
1,586,051
Net Income from Continuing Operation Net Minority Interest
-19,476,774.57
-19,476,774.57
-12,728,376.38
-36,297,830.14
-13,602,674.40
Total Unusual Items Excluding Goodwill
-531,692
-531,692
-51,956
-14,696,748
-144,576
Total Unusual Items
-531,692
-531,692
-51,956
-14,696,748
-144,576
Normalized EBITDA
-12,743,526.60
-12,743,526.60
-10,566,469.92
-19,131,098.52
-10,971,570.76
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-127,606.08
-127,606.08
-12,469.44
-4,041,605.70
-36,144
12/31/2021 - 1/20/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade